Product image of Nebivolol Evolugen (Nebivolol Hydrochloride) supplied by GNH India

Nebivolol Evolugen

Active Ingredient:
Nebivolol Hydrochloride
Origin:
EU

Nebivolol Evolugen (Nebivolol Hydrochloride)

Nebivolol Hydrochloride, the active ingredient in Nebivolol Evolugen, is a beta blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension and heart failure in adult patients.
GNH India supplies Nebivolol Evolugen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Evolupharm

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nebivolol Hydrochloride acts on the cardiovascular system to lower blood pressure and improve cardiac output.

  • Hypertension: reduces systolic and diastolic pressure, helping to achieve target blood pressure goals.
  • Heart failure: improves left‑ventricular ejection fraction and reduces symptoms of chronic heart failure.

How It Works

  • Nebivolol Hydrochloride selectively blocks β1‑adrenergic receptors, decreasing heart rate and myocardial contractility. In addition, it stimulates endothelial nitric oxide release, causing vasodilation and further lowering peripheral resistance. This dual action results in reduced blood pressure and improved cardiac efficiency without significant β2‑mediated bronchial effects.

Side Effects

Nebivolol Hydrochloride may cause adverse reactions that vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate pain often occurring early in therapy.
  • Dizziness or light‑headedness: related to blood‑pressure reduction.
  • Fatigue: generalized tiredness, especially during dose titration.
  • Bradycardia: heart rate below 60 bpm in some patients.

Serious or Rare Side Effects

  • Severe bradycardia or heart block requiring medical attention.
  • Acute bronchospasm in patients with underlying airway disease.
  • Hepatic injury manifested by elevated transaminases.
  • Allergic reactions such as rash, angioedema, or anaphylaxis.

Precautions & Warnings

Nebivolol Hydrochloride requires careful monitoring and patient education before and during treatment.

  • Blood pressure monitoring: check regularly to avoid excessive hypotension.
  • Cardiac assessment: evaluate heart rate and ECG, especially in patients with conduction disorders.
  • Concomitant beta‑blockers: avoid combining with other β‑blockers to prevent additive effects.
  • Renal/hepatic impairment: dose adjustment may be needed in moderate to severe dysfunction.
  • Discontinuation: do not stop abruptly; taper under medical supervision to prevent rebound hypertension.
  • Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Nebivolol Hydrochloride can interact with several drug classes, influencing its safety and efficacy.

Major Interactions (Avoid)

  • Calcium‑channel blockers (verapamil, diltiazem): may cause marked bradycardia or AV block.
  • CYP2D6 inhibitors (paroxetine, fluoxetine, quinidine): increase nebivolol plasma levels.
  • Other antihypertensives (ACE inhibitors, ARBs) used in high doses: risk of additive hypotension.

Moderate Interactions (Monitor Closely)

  • Diuretics: may enhance orthostatic hypotension; monitor electrolytes.
  • NSAIDs: can blunt antihypertensive effect; assess blood pressure response.
  • Antidiabetic agents: nebivolol may mask hypoglycaemia symptoms; monitor glucose levels.

Frequently Asked Questions

Nebivolol Evolugen contains nebivolol hydrochloride, a beta‑blocker indicated for the treatment of essential hypertension and for chronic heart failure in adult patients. It helps lower blood pressure and improve cardiac function by reducing heart rate and promoting vasodilation.

Nebivolol selectively blocks β1‑adrenergic receptors, decreasing heart rate and myocardial contractility. It also enhances endothelial nitric oxide release, leading to vasodilation. The combined effect reduces peripheral resistance and blood pressure while supporting cardiac output in heart‑failure patients.

The appropriate dose of Nebivolol Evolugen is determined by the prescribing clinician based on the patient’s clinical condition, blood‑pressure response, and tolerability. Dosage adjustments may be required for renal or hepatic impairment, and the regimen should follow the prescriber’s instructions.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a highly selective β1‑blocker with additional nitric‑oxide‑mediated vasodilation, which can result in fewer metabolic side effects compared with non‑selective beta‑blockers. This profile may offer better tolerability in patients with respiratory conditions or diabetes, while still providing effective blood‑pressure control.

Nebivolol Evolugen should be stored at ambient temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Nebivolol Evolugen is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, atrioventricular block, bronchospasm in patients with obstructive airway disease, and rare cases of hepatic injury. Patients should be monitored for signs of these events, and therapy should be discontinued if they occur.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any component of the formulation, in those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, and in patients with uncompensated heart failure. Caution is also advised for individuals with asthma or chronic obstructive pulmonary disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Nebivolol Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT